Tekla Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Tekla Capital Management's REGN Position: Q2 2023 in Review
Tekla Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 13% in Q2 2023, buying an estimated $14.2M and bringing the position to 161,418 shares worth $116M. The position accounts for 4.54% of the portfolio, ranked #4.
Tekla Capital Management first reported a position in REGN in Q2 2013 and has held it in 41 quarters since. The position peaked at $118M in Q1 2023. 1,166 funds tracked by Wall St. Rank hold REGN as of Q2 2023.
- Tekla Capital Management held 161,418 shares of Regeneron Pharmaceuticals worth $116M as of Q2 2023.
- Tekla Capital Management bought 18,365 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $14.2M.
- Regeneron Pharmaceuticals made up 4.54% of Tekla Capital Management's portfolio in Q2 2023, its #4 holding.
- Tekla Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
- Tekla Capital Management's Regeneron Pharmaceuticals position peaked at $118M in Q1 2023.
- 1,166 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.
Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.